Study tracks stroke victim's restored communication ability

A Weill Cornell Medicine study published Dec. 7 represents the first time scientists have captured the restoration of communication of a minimally conscious patient by measuring aspects of brain structure and function.

Neuroimaging categorizes four depression subtypes

Patients with depression can be categorized into four unique subtypes defined by distinct patterns of abnormal connectivity in the brain, according to new research from Weill Cornell Medicine.

Complications arise from mesh used in pelvic surgeries

A synthetic mesh commonly used to treat urinary incontinence and weakening of female pelvis walls can lead to complications, new Weill Cornell Medicine research suggests.

Cancer cells 'talk' to their environment, and it talks back

A Cornell-led team has devised a method for measuring the mechanical force cells exert on their surroundings, which can help scientists design better biomaterial scaffolds for tissue engineering.

Barrett, Leibovich and Walsh named AAAS fellows for 2016

Three faculty members - development economist Chris Barrett, mechanical engineer Sidney Leibovich and medical mycologist Dr. Thomas Walsh - have been named fellows of the American Association for the Advancement of Science.

NYC high schoolers discover opportunity at Big Red STEM Day

The first Big Red STEM Day exposed high school students from communities underrepresented in science, technology, engineering and mathematics to educational and career opportunities in those fields.

Cells implicated in dementia related to high blood pressure

High blood pressure transforms cells of the immune system that reside around cerebral blood vessels and normally protect the brain into agents of cognitive decline, according to new research from Weill Cornell Medicine scientists.

Weill Cornell partners in innovative drug discovery company

Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced Oct. 31 that they have established a new drug discovery company called Bridge Medicines.

$2M gift to drive Weill Cornell advances in immunotherapy

To advance a powerful cancer treatment strategy that uses immune cells to fight the disease, Ellen and Gary Davis '76 have made a $2 million gift to Weill Cornell Medicine to drive ongoing research in immunotherapy.